News | Digital Pathology | December 07, 2020

Philips Boosts Digital Pathology with Enhanced Informatics to Advance Precision Diagnosis in Oncology

Latest iteration of Philips IntelliSite Pathology Solution helps support pathologists to work more efficiently in an automated digital workflow

Latest iteration of Philips IntelliSite Pathology Solution helps support pathologists to work more efficiently in an automated digital workflow

December 7, 2020 — Philips, a global leader in health technology, today announced it will introduce its latest advancements in digital pathology at the European Congress of Pathology 2020 virtual event, Dec. 6-8. Building on its strong portfolio to support oncology clinical decision-making, Philips brings together the power of imaging, pathology, genomics and longitudinal data with insights from artificial intelligence, to empower clinicians to deliver clear care pathways with predictable outcomes for every patient.

Pathology is vital to healthcare delivery, with 70% of decisions affecting a person’s life involving a laboratory or pathology test. However, with current resource shortages, the growing volume of complex requests, and workflow inefficiencies across systems and departments, pathology labs are facing major pressures on multiple fronts. 

Rather than viewing oncology as many single moments of care, Philips envisions a continuous care pathway empowered by integrated solutions for oncology and pathology that help transform and enhance multi-disciplinary workflows, including the oncology tumor board process. Critical patient data is made visible for both oncologists and pathologists, which allows them to collaborate more efficiently, to drive the right care in the right sequence at the right time.

By taking a systems view across the imaging enterprise, Philips leverages the power of smart diagnostic technologies and advanced informatics to remove the obstacles standing in the way of optimized workflows. The newly released Philips IntelliSite Pathology Solution features a leading-edge user experience (UX), enhancing ease of use while helping streamline the imaging workflow in an automated digital solution. With this latest iteration, Philips connects healthcare systems to scale digital operations and improve efficiency in high volume scanning, stimulate collaboration and enable precision diagnosis. 

Philips commitment to an open pathology platform

Philips IntelliSite Pathology Solution offers an open, scalable, and interoperable platform that supports flexibility in deployments of image analysis software tools, strengthening Philips commitment to the Open Pathology platform. Other software  tools allow developers and researchers to work with data natively in the iSyntax format for core research and algorithm development, enabling collaboration for education and the creation of third-party applications.

“A precise diagnosis informs the patient’s care pathway progress, from screening and diagnosis to treatment, monitoring, assessment, and the transition toward home care,” said Kees Wesdorp, Chief Business Leader Precision Diagnosis at Philips. ”Philips integrated solutions for oncology, including this latest enhancement in digital pathology, help empower the cancer care team to reach clinical treatment decisions based on richer dashboards, clinical images, reports, and structured patient data. The seamless integration of information into the oncology workflow will help improve the clinician experience and ultimately, patient outcomes.”

For more information: www.philips.com/digitalpathology


Related Content

Radiologists of Leuwiliang General Hospital using Lunit INSIGHT CXR and INFINITT PACS G7

Radiologists of Leuwiliang General Hospital using Lunit INSIGHT CXR and Infinitt PACS G7.

News | Coronavirus (COVID-19) | January 27, 2021
January 27, 2021 — Lunit, a South Korean medical...
The key trends Clinicians reviewing a COVID-19 patient's lung CT that reveals the severity of COVID-caused pneumonia. The impact of COVID on radiology was a major, over arching trend at  the 2020 Radiological Society of North America (RSNA) meeting. Getty Imagesbserved at 2020 Radiological Society of North America (RSNA) meeting all focused around COVID-19 (SARS-CoV-2) and the impact it has had on radiology. #RSNA #RSNA20 #RSNA2020

Clinicians reviewing a COVID-19 patient's lung CT that reveals the severity of COVID-caused pneumonia. The impact of COVID on radiology was a major, over arching trend at  the 2020 Radiological Society of North America (RSNA) meeting. Getty Images

Feature | RSNA | January 20, 2021 | By Melinda Taschetta-Millane and Dave Fornell
MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI.

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI. Image courtesy of Exact Imaging

Feature | Prostate Cancer | January 20, 2021 | By Brian Wodlinger, Ph.D.
Historically when a patient had an elevated PSA (prostate specific antigen) test their urologist would take the next
The exceptionally high dose rate of the FLASH Beam is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the therapy its nickname, "FLASH." Image courtesy of Brian Pogue, PhD

The exceptionally high dose rate of the FLASH Beam is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the therapy its nickname, "FLASH." Image courtesy of Brian Pogue, PhD

News | Linear Accelerators | January 20, 2021
January 20, 2021 — A joint team of researchers from Radiation Oncology at Dartmouth's and...
AI Metrics, LLC, a medical imaging startup focused on augmented intelligence to improve patient care, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s flagship image analysis platform.
News | Artificial Intelligence | January 18, 2021
January 18, 2021 — AI Metrics, LLC, a medical imaging startup focused on augmented intelligence to improve patient ca
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...